HAYWARD, Calif. & CAMBRIDGE, England, Sep 08, 2005 (BUSINESS WIRE) -- Solexa, Inc. (Nasdaq:SLXA) today announced that Gary Schroth, Ph.D., Director of Expression Applications R&D, will conduct a technology workshop on the use of Solexa's DNA Cluster Sequencing-By-Synthesis (SBS) technology for comprehensive digital gene expression profiling. Dr. Schroth's workshop entitled, "Generating Cost-Effective Digital Genome-Wide Expression Analysis using Cloned Single-Molecule Arrays(TM)," will be presented at the 12th Annual Chips to Hits(R) Conference on Tuesday, September 13, 2005 beginning at 3:45 p.m. Eastern Time in Boston.

"DNA Cluster-SBS technology has the advantage of producing highly accurate, reproducible and quantitative readouts of the full complement of activated genes or small RNA in a particular tissue without requiring advance knowledge of gene structure or coding sequence," stated John West, Solexa's chief executive officer. "Furthermore, we expect that Solexa's technology will generate this digital data at costs comparable to those of analogue methods currently in use."

Solexa is developing DNA Cluster-SBS as a next-generation sequencing technology that can be used in a range of expression applications, both as a discovery and a validation tool. Among the primary applications of the platform will be tag-based digital expression profiling, full-transcriptome sequencing for the discovery and quantification of transcript variants and coding SNPs, and discovery and quantification of small RNA species. Since Solexa's approach to expression profiling does not require any a priori knowledge of the transcriptome, the technology will enable sequencing-based expression profiling of any transcript, from any gene, in any organism, including those with poorly annotated genomes. Solexa expects to introduce its Cluster-SBS instruments in late 2005 and to begin commercial sale in 2006.

About Solexa

Solexa, Inc. is developing and preparing to commercialize a new genetic analysis instrument system which will be used to perform a range of analyses including whole genome resequencing, gene expression analysis and micro-RNA analysis. We expect Solexa's first-generation technology to generate over a billion bases of DNA sequence per run and to enable whole genome resequencing below $100,000 per sample, making it the first platform to reach this important milestone. Solexa's longer-term goal is to reduce the cost of human re-sequencing to a few thousand dollars for use in a wide range of applications from basic research through clinical diagnostics. The Company expects to introduce its first instrument system by the end of 2005. For further information, please visit www.solexa.com.

This press release contains "forward-looking" statements, including statements related to the current views of Solexa management as to future products, product development including the commercial introduction of the Company's novel genetic analysis technology, the expansion and success of Solexa's commercial application of its genomics technologies, the availability of adequate funding for Solexa and the future financial performance of Solexa. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "predicts," "expects," "envisions," "hopes," "estimates," "intends," "will," "continue," "may," "potential," "should," "confident," "could" and similar expressions are intended to identify forward-looking statements. There can be no assurance that such expectations of any of the forward-looking statements will prove to be correct, and actual results could differ materially from those projected or assumed in the forward-looking statements. There are a number of important factors that could cause the results of Solexa to differ materially from those indicated by these forward-looking statements including, among others, risks detailed from time to time in the Company's SEC reports, including its Annual Report on Form 10-K for the year ended December 31, 2004 and its Form 10-Q for the quarter ended June 30, 2005. Solexa does not undertake any obligation to update forward-looking statements.

SOURCE: Solexa, Inc.

Solexa, Inc.
Omead Ostadan, 510-670-9300
oostadan@solexa.com
or
European Media Contact:
Northbank Communications
Sue Charles, +44 (0)20 7886 8152
s.charles@northbankcommunications.com
or
Investor Contacts:
Lippert/Heilshorn & Associates
Jody Cain (jcain@lhai.com)
Bruce Voss (bvoss@lhai.com)
or
U.S. Media Contact:
Mark Stuart (mstuart@lhai.com)
310-691-7100